Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients
ConclusionSarcopenia is a strong risk factor for treatment discontinuation and reduced progression-free survival in glioblastoma patients. We propose that sarcopenic patients should receive intensified supportive care during radiotherapy and during follow-up as well as expedited access to palliative care.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Corticosteroid Therapy | CT Scan | Palliative | Palliative Care